Compositions and methods of producing composite materials for use as a cathode in electrochemical cells. Elemental sulfur is mixed with tungsten sulfide (WS.sub.2) to form a composite mixture. Organic comonomers may be added to the composite mixture. The composite mixture is reacted to form the composite material. Electrochemical cells with cathodes containing the composite material demonstrated improved battery performance.

Compositions and methods of producing composite materials for use as a cathode in electrochemical cells. Elemental sulfur is mixed with tungsten sulfide (WS.sub.2) to form a composite mixture. Organic comonomers may be added to the composite mixture. The composite mixture is reacted to form the composite material. Electrochemical cells with cathodes containing the composite material demonstrated improved battery performance.

Provided are combinations comprising terbinafine or a pharmaceutically acceptable salt thereof and a NO source. The combination may be a synergistic combination. Also provided are methods of treating and/or preventing a fungal infection in a subject comprising administering terbinafine or a pharmaceutically acceptable salt thereof to the subject; and administering a NO source to the subject, thereby treating and/or preventing the fungal infection in the subject. The dose of terbinafine or a pharmaceutically acceptable salt thereof and the dose of the NO source administered to the subject may achieve a synergistic effect.

Provided are combinations comprising terbinafine or a pharmaceutically acceptable salt thereof and a NO source. The combination may be a synergistic combination. Also provided are methods of treating and/or preventing a fungal infection in a subject comprising administering terbinafine or a pharmaceutically acceptable salt thereof to the subject; and administering a NO source to the subject, thereby treating and/or preventing the fungal infection in the subject. The dose of terbinafine or a pharmaceutically acceptable salt thereof and the dose of the NO source administered to the subject may achieve a synergistic effect.

Sulfur composites and polymeric materials having a high sulfur content and prepared from elemental sulfur as the primary chemical feedstock. The sulfur copolymers are prepared by the polymerization of elemental sulfur with one or more monomers of amines, thiols, sulfides, alkynylly unsaturated monomers, nitrones, aldehydes, ketones, thiiranes, ethylenically unsaturated monomers, or epoxides. The sulfur copolymers may be further dispersed with metal or ceramic composites or copolymerized with elemental carbon, photoactive organic chromophores, or reactive and solubilising/biocompatible moieties. The sulfur composites and polymeric materials feature the ability self-healing through thermal reformation. Applications utilizing the sulfur composites and polymeric materials may include electrochemical cells, optics, H.sub.2S donors and antimicrobial materials.

Various embodiments disclosed relate to treatment of fungal infections. The present invention provides a method of treating a fungal infection including contacting a fungus including a -glucan that is at least partially masked from immune system detection with a therapeutically effective amount of a compound that at least partially unmasks the -glucan to increase immunogenicity of the fungus.

Various embodiments disclosed relate to treatment of fungal infections. The present invention provides a method of treating a fungal infection including contacting a fungus including a -glucan that is at least partially masked from immune system detection with a therapeutically effective amount of a compound that at least partially unmasks the -glucan to increase immunogenicity of the fungus.

Provided herein are a reactive oxygen species (ROS) scavenging composition, a method of forming a ROS scavenging composition, and a method of treating a subject having a (ROS) perpetuated disease. The ROS scavenging composition includes a co-polymer of a hydrophilic monomer and a grafting monomer, and a ROS scavenging compound grafted to the grafting monomer. The method of forming a ROS scavenging composition includes forming a co-polymer of a hydrophilic monomer and a grafting monomer, and grafting ROS scavenging compound onto the co-polymer. The method of treating a subject having a ROS perpetuated disease includes administering a therapeutically effective amount of an ROS scavenging composition comprising a co-polymer of a hydrophilic monomer and a grafting monomer, and a ROS scavenging compound grafted to the grafting monomer, to the subject in need thereof.

A medical material uses a nickel-titanium alloy wherein a polyelectrolyte has a reduced thickness while a sufficient amount of an antithrombogenic compound for production of a therapeutic effect is supported. The medical material in which a porous surface is formed on a nickel-titanium alloy to allow infiltration of a polyelectrolyte into the pores, to thereby reduce the thickness of the polyelectrolyte exposed on the surface of the nickel-titanium alloy while allowing supporting of a sufficient amount of an antithrombogenic compound due to contribution of the polyelectrolyte infiltrate.

Polythioaminal polymers are made from hexahydrotriazine precursors and dithiol precursors. The precursors are blended together and subjected to mild heating to make the polymers. The polymers have the general structure ##STR00001##
wherein each R.sup.1 is independently an organic or hetero-organic group, each R.sup.2 is independently a substituent having molecular weight no more than about 120 Daltons, X and Z are each a sulfur-bonded species, at least one of X and Z is not hydrogen, and n is an integer greater than or equal to 1. X and Z may be hydrogen or a functional group, such as a thiol-reactive group. The reactive thiol groups of the polythioaminal may be used to attach thiol-reactive end capping species. By using water soluble or water degradable dithiols, such as polyether dithiols, water soluble polythioaminals may be made. Some such polymers may be used to deliver therapeutics with non-toxic aqueous degradation products.